KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Dec 2024 value amounting to $294.2 million.

  • Alnylam Pharmaceuticals' Cash from Financing Activities fell 536.33% to -$448.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$319.5 million, marking a year-over-year decrease of 205.66%. This contributed to the annual value of $294.2 million for FY2024, which is 70.89% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $294.2 million for FY2024, which was up 70.89% from $172.1 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Cash from Financing Activities ranged from a high of $1.2 billion in FY2021 and a low of $172.1 million during FY2023.
  • For the 3-year period, Alnylam Pharmaceuticals' Cash from Financing Activities averaged around $297.3 million, with its median value being $294.2 million (2024).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Cash from Financing Activities slumped by 65.86% in 2022 and then spiked by 70.89% in 2024.
  • Alnylam Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $995.0 million in 2020, then rose by 25.34% to $1.2 billion in 2021, then crashed by 65.86% to $425.8 million in 2022, then tumbled by 59.57% to $172.1 million in 2023, then soared by 70.89% to $294.2 million in 2024.